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Axonal injurynds to the axonal cytoarchitecture leaving its signature on axoskeletal proteins.
This study investigated whether neuroﬁlament (NfH) phosphorylation would relate to the dynamics of
axonal pathology in multiple sclerosis (MS).
Methods: NfH phosphoforms (SMI32, SMI34, SMI35) were quantiﬁed by ELISA from microdissected samples
of control and MS brain and spinal cord. Individual axons were analysed by electron microscopy,
densitometrically and morphologically in adjacent tissue sections. Experiments were carried out pre- and
post enzymatic dephosphorylation.
Results: In control tissue a rostro-caudal gradient of NfH indicated an increase in axonal density from the
brain gray matter towards the spinal cord. The highest levels of phosphorylated and hyperphosphorylated
NfH were found in acute lesions of brain and spinal cord, in contrast to chronic lesions where levels were
lower than in white matter, consistent with axonal loss. Dephosphorylated NfH was higher, but less densly
packed in MS white matter axons compared to control tissue.
Conclusions: The ﬁndings suggest that a less organised/compact axoskeleton or impaired axonal transport
may represent an early sign of axonal pathology within the normal appearing white matter in MS.
Subsequently a proportional increase of dephosphorylated NfH, aberrant phosphorylation and/or aggrega-
tion may occur whilst the protein is transported through the white matter towards the MS plaque, where
hyperphosphorylated NfH dominates.
© 2008 Elsevier Inc. Open access under CC BY license.Introduction
Multiple sclerosis (MS) is an inﬂammatory demyelinating disease
in which axonal loss (Ferguson et al., 1997; Trapp and Peterson, 1998;
Bitsch et al., 2000), thought to be the main pathological substrate for
irreversible disability, is the dominant pathological feature of the
degenerative phase of the disease (reviewed in (Lassmann et al.,
2007; Bjartmar and Trapp, 2001; Esiri, 2007). In chronic MS patientsosphatase; BSP, brain-speciﬁc
m; CTRL, control group; EDSS,
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 license.about 50% of demyelinated spinal cord axons showed an abnormally
fragmented axoplasm compared to about 4.8% of myelinated axons
(Dutta et al., 2006). The ﬁnding was attributed to altered neuroﬁla-
ment (Nf) spacing. Neuroﬁlaments are proteins speciﬁcally designed
for post-translational modiﬁcations within the axonal compartment.
Neuroﬁlament phosphorylation increases Nf spacing and thereby
axonal caliber (Grant and Pant, 2000; Lee and Cleveland, 1996;
Petzold, 2005). The distinguishing feature of the Nf heavy chain
(NfH) is its long tail with multiple KSP repeats acting as the main
phosphorylation sites (see Fig. 1). Phosphorylation of the NfH KSP
repeats is inﬂuenced by Ca2+ inﬂux, glutamate, NGF and ﬁbrin (Grant
and Pant, 2000; Brownlees et al., 2000; Schwarzschild et al., 1999;
Xia et al., 1996; Akassoglou et al., 2002). All of these mechanisms
feature in the pathophysiology of MS. The pattern of NfH
phosphorylation in staged lesions of MS and control brain tissue is
not known.
In the present study we investigate the quantitative distribution of
NfH phosphoforms inmicrodissected brain and spinal cord tissuewith
the aim of (1) outlining the topography of NfH phosphoforms in
control tissue and (2) comparing NfH phosphoforms from control
Fig. 1. Conformational changes of the NfH protein due to phosphorylation expose and hide antibody-binding epitopes. Hyperphosphorylated NfH is recognised by the antibodies
SMI34 and SMI35 and phosphorylated NfH by SMI35. Dephosphorylated NfH is strongly recognised by the antibody SMI32. ALP=alkaline phosphatase.
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tissue.
Materials and methods
Subjects
Patients with secondary MS according to the Poser criteria and
age-matched controls were included in the study. All MS patients
were classiﬁed as secondary progressive with signiﬁcant disability
(EDSS 9–10) (Gveric et al., 2001). Tissue was kindly provided by the
Neuroresource Tissue Bank at the Institute of Neurology. We have
previously published on this cohort with regard to glial biomarkers
(Petzold et al., 2002) and the ﬁbrinolytic system in brain tissue
(Gveric et al., 2001; Gveric et al., 2003). Tissue sampling has been
extended and spinal cord tissue was included to enable a more
global and systematic assessment in the present study. In total, 77
snap-frozen tissue blocks (0.5–1 cm3) were analysed.
Immunocytochemistry
For immunocytochemistry, 10 µm cryostat sections were
immunoperoxidase-stained with antibodies directed against
SMI32, SMI34 and SMI35 (Sternberger Monoclonals Inc., Lutherville,
USA), GFAP, (Newcombe, 1986) 14E for oligodendrocytes and
reactive astrocytes (Newcombe et al., 1992). Cryostat sections
were ﬁxed in methanol (−20 °C, 10 min), incubated with primary
antibody overnight (4 °C) and stained using a three-step peroxidase
method (Gveric et al., 1999). Adjacent sections were incubated with
0 mU (control), 10 mU, 100 mU or 1000 mU alkaline phosphatase
(Sigma, P4252) in Tris–HCl buffer (100 mM Tris, pH 8.1 with 1%
Triton X-100), at room temperature for 18 h prior to immunostain-
ing as described (Sternberger and Sternberger, 1983). Omission of
primary antibodies and the application of afﬁnity puriﬁed rabbit
(Dako), goat (Sigma) and mouse IgG (Sigma) were used as
controls at the same protein concentrations as the appropriate
primary antibodies. Images were photgraphed on a Leitz DMRB
microscope using a 1/125 exposure time on a Nikon Coolpix 995
camera (3.34 megapixels).Lesion classiﬁcation
Unﬁxed post-mortem brain tissue was histologically classiﬁed into
normal-appearing white matter (NAWM), acute lesions (AL), chronic
lesions (CL) and gray matter (GM) from MS patients using previously
published criteria (Newcombe and Cuzner, 1996). Adjacent pieces of
each type of tissue were excised and homogenised as described
(Petzold et al., 2003a,b). This study did not include remyelinated
lesions or cortical demyelination.
Electron microscopy
Standard protocols were used for electron microscopy (EM). In
brief, post-mortem brain tissue samples were taken from the
frontal periventricular white matter and ﬁxed for 1 h in 4%
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4). The
samples were then cut into 1 mm cubes, washed in PBS and
processed into araldite CY 212 for EM. Ultrathin sections were cut
from the surface of the tissue, stained with uranyl acetate and lead
citrate, and examined at 80 kV.
Image analysis
Images were analysed on a LINUX workstation using the GNU
Image Manipulation Program (GIMP is distributed under the GNU
General Public License and can be obtained free of charge from
www.gimp.org). For densitometric analysis sections of individual
axons were used. For each axon, the diameter was measured
using the number of pixels as an arbitrary unit. Next, a his-
togram of the pixel intensity was obtained on a grey-scale
ranging from 0 (black) to 255 (white). The mean pixel intensity
(±SD), range and the absolute pixel number per axon were
recorded. Because background intensity varied between slides, the
mean background intensity was subtracted from the mean
intensity for each axonal measurement. The estimated optical
density (OD), was then expressed as the ratio of 1 to the mean
pixel intensity as an arbitrary unit. Finally, the ratio of OD to
axonal diameter was used in order to express the compactness of
axonal NfH.
Fig. 2. Enzymatic dephosphorylation of puriﬁed NfH with ALP. (A) The Western blot
shows a band for phosphorylated NfH (lane 2) at ≈210 kDa and for ALP (31 kDa)
dephosphorylated NfH (lane 4) at ≈190 kDa. The immunoblots demonstrate that SMI34
binds selectively to phosphorylated NfH (lane 5) and SMI32 selectively to ALP
dephosphorylated NfH (lane 8). (B) Dephosphorylation of NfH with ALP is dose
dependent. Incubation with ≈2 mU ALP at 37° for 2 h (pH 10.3) is needed to mask the
phosphorylated epitopes recognised by the SMI34 (closed line) and unmask the non-
phosphorylated epitopes recognised by SMI32 (dotted line).
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Snap-frozen blocks of brain tissue from MS and control cases of
between 0.5 g and 1 g wet weight, were cut and re-suspended at
1:5 g/mL in Tris–HCl buffer (100 mM Tris, pH 8.1 with 1% Triton
X-100). A protease inhibitor cocktail (Sigma, P 8340) was added in a
dilution 1:100. Samples were homogenised on ice by sonication,
triturated 3 times through 19 and 21 gauge needles and spun at
20,000 g. In order to de-lipidise the sample diisopropyl ether was
added. After extensive mixing, the sample was spun at 20,000 g. The
supernatant was covered by a myelin layer. A needle was put through
the myelin layer and only the supernatant drawn up into a 1 mL
syringe. The myelin layer and pellet were decanted. The supernatant
was aliquotted into 2 portions.
Dephosphorylation
It has been suggested that dephosphorylation uncovers epitopes
particularly accessible to SMI32, which are otherwise hidden
(Sternberger and Sternberger, 1983) (Fig. 1). Therefore one aliquot of
the tissue homogenate was subjected to enzymatic dephosphoryla-
tion by using alkaline phosphatase (ALP, Sigma, P4252) which
dephosphorylates Nf (Grant and Pant, 2000).
Barbitone buffer was selected for NfH incubationwith ALP because
it is inert to enzyme activity (Moss and Henderson, 1994, p. 831). The
optimum pH for the different alkaline phosphatase isoforms varies
from about 8.5 to 10.5, thus enabling direct incubation into the sample
buffer (pH 8.9) (Petzold et al., 2003a,b).
Western- and Immunoblotting
A tris-acetate gel (3–6%, NuPage) was used for Western- and
immunoblotting. The gel was loaded with 5 μL of molecular weight
markers (Invitrogen, Novex P/N57318 for the Coomassie stain and
MagicMark XP P/N LC5602 for chemiluminescence). Thirty microlitre
of sample were loaded per lane. The sample contained either puriﬁed
NfH (12.5 μg/mL), puriﬁed NfH (12.5 μg/mL) together with ALP
(50 μg/mL) or ALP alone (50 μg/mL). The gel was run for 1.5 h using
TrisAcetate SDS running buffer (Novex, LA0041) at 150 V. The gel was
cut in three parts: lanes 1–4 for Coomasie stain, lanes 5–7 for incu-
bation with the SMI34 antibody and lanes 8–10 for incubation with
the SMI32 antibody. For the immunoblot proteins were transferred
onto nitrocellulose (Novex transfer buffer, NP00061, at 25 V for 2 h).
The membranes were blocked in 5% skimmed milk (barbitone buffer)
for 1 h. The membranes were washed and incubated in 0.1% skimmed
milk (barbitone buffer) with monoclonal mouse anti-NfH antibodies
(SMI341:1000, SMI321:1000) at 4 °C overnight. Themembraneswere
washed 6 times for 10 min, incubated with HRP-labeled rabbit anti
mouse (DAKO, P0260, 1:1000) and washed as before. The membranes
were incubated with the chemiluminescence substrate (SuperSingal
West Pico, Thermo Scientiﬁc, #34078) for 5 min. The dried mem-
branes were visualised on a AlphaEase FluorChem SP CCD camera
(20 s for SMI34 and 7 min for SMI32).
The Coomassie stain shows a band at approximately 200 kDa for
phosphorylated NfH (lane 2 in Fig. 2A). ALP gives a strong band at
≈31 kDa (lanes 3 and 4). ALP dephosphorylated NfH shows a band at
≈190 kDa (lane 4). The immunoblots show that SMI34 binds selectively
to phosphorylated NfH (lane 5) and SMI32 to dephosphorylated NfH
(lane 8). There is no cross-reactivity of either antibody with ALP.
Assays
Levels of NfH phosphoforms were quantiﬁed using an in-house
ELISA technique as described (Petzold et al., 2003a,b). All samples
were analysed in duplicate and repeated if the error between
duplicates exceeded 10%. The monoclonal antibodies SMI32, SMI34and SMI35 were purchased from Sternberger Monoclonals Inc. (these
antibodies are now supplied by Covance). Fig. 1 summarises the
antibody binding properties.
As proof-of-principle HPLC-puriﬁed bovine NfH (Afﬁniti Research
Products) was incubated with ALP at different concentrations ranging
from 0.2 mU to 125 mU for 2 h at 37 °C. ALP denatures above 56 °C,
therefore incubation for 10 min at 60 °C was used for stopping the
enzymatic reaction. The untreated control samples were subjected to
the same procedure and incubated with an equal volume of sample
buffer. The effect enzymatic dephosphorylation has on covering the
epitopes recognised by SMI34 and uncovering the epitopes recognised
by SMI32 is shown in Fig. 2. Complete dephosphorylation of the
phospho-epitope recognised by SMI34 was achieved following
dephosphorylation with 2 mU ALP. However unmasking of the non-
phosphorylated epitope recognised by SMI32 required a higher
Table 1
Subject characteristics
Characteristic Controls Multiple sclerosis Signiﬁcance
Number 15 20
Sex (female:male) 3 (20%): 12 (80%) 11 (55%): 9 (45%) pb0.05
Age (yrs) 65 (34–80) 59 (29–77) N.S.
Post-mortem interval (hours) 21 (11–52) 15.5 (4–71) N.S.
Disease duration (yrs) N/A 20 (8–43)
Cause of death
Heart failure 6 (40%) 1 (5%)
Myocardial infarction 4 (27%) 0 (0%)
Bronchopneumonia 2 (13%) 14 (70%)
Pulmonary embolism 1 (7%) 0 (0%)
Sepsis 0 (0%) 3 (15%)
Renal failure 1 (7%) 1 (5%)
Liver carcinoma 1 (7%) 0 (0%)
Bowel carcinoma 0 (0%) 1 (5%)
All data are shown as number (%), median (range), N.S.=not signiﬁcant.
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patients' samples were incubated with 100 mU of ALP for 18 h at room
temperature. Fig. 2B demonstrates that the degree of dephosphoryla-
tion was sufﬁcient to completely mask the epitope recognised by
SMI34 (shown in the immunoblot in Fig. 2A) from the spinal cord
homogenates. All aliquots were then stored at −70 °C until further
analysis.
Total proteinwas determined using the Bio-Rad Protein assay (Bio-
Rad, Hemel Hempstead, UK).
Data analysis
All statistical and data analyses were carried out using SAS (version
9.1, SAS Institute, Inc., Cary, North Carolina, USA). The 2-tailed non-
parametric two-sample exact Wilcoxon rank–sum test was used forFig. 3. Immunocytochemistry for phosphorylated (SMI35) and dephosphorylated (SMI32) NfH
[NAWM] far away from any lesion (left section in the slides), normal-appearing white matte
lesion [AL, right section of the slides]. The sections were incubated with (A, C) buffer on
immunostaining with either SMI32 or SMI35 (×10).comparing two groups and a 2-tailed two-way unbalanced ANOVA
(general linear model, GLM) for more than two groups. If signiﬁcance
was based on small numbers (nb10), the results were also subjected
to Fisher's exact test comparing proportions of samples above or
below cut-off. The cut-off was deﬁned as the 100% cumulative
frequency of the subgroup with the lowest values. Trend analysis
was done using Mantel–Haenzels χ2 test. Correlation analysis was
performed using the Spearman Correlation Coefﬁcient followed by the
Bonferroni correction in case of multiple analyses. A p-value of b0.05
was accepted as signiﬁcant if shown on the discrete (GLM and post-
hoc) and the categorical level (Fisher's exact test). The p-values for the
GLM post-hoc analysis are given in the Tables and for Fisher's exact
test in the Figures.
Results
The patients' characteristics are summarised in Table 1. Therewere
no signiﬁcant differences in the age distribution or the post-mortem
interval, but there were more females in the MS group than in the
control group (pb0.05).
There was no correlation for any of the NfH phosphoforms with
either the post-mortem interval, the age or the disease duration.
The effect of dephosphorylation (see Fig. 1) is demonstrated by
immunocytochemistry in Fig. 3. In untreated MS tissue mainly axonal
end-bulbs stained for SMI32 (Fig. 3A). Most end-bulbs were observed
in the AL, some in the NAWM adjacent to the lesion and only very
few in NAWM distal to lesions. Treatment with ALP uncovered
previously hidden epitopes (Sternberger and Sternberger, 1983) and
revealed a much richer network of axons (Fig. 3B) involving the
entire NAWM. In contrast, staining for SMI35 which recognises
phosphorylated epitopes on NfH was clearly reduced in NAWM after
dephosphorylation and to a lesser degree in AL (Figs. 3C, D). At the
border of chronic lesions (CL), treatment with ALP did reducein longitudinal sections along axonal trajectories from normal-appearing white matter
r adjacent to the acute lesion [NAWM (AL), central section in the slides] and the acute
ly (0.1 M Tris–HCl pH 8.0) or (B, D) 100 mU ALP in buffer for 18 h at 37 °C before
Fig. 4. Immunocytochemistry of a chronic plaque featuring dephosphorylated NfH (A, B) and phosphorylated NfH (C, D). (A, C) show untreated and (B, D) sections (×10).
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impression that phosphorylated NfH might “pile up” (Fig. 4D). As
before, enzymatic dephosphorylation increased the staining for non-
phosphorylated NfH (Figs. 4A, B), again giving the impression that it
may “pile up” at the border of the CL (Fig. 4B).
As expected from the immunocytochemical data, treatment with
ALP almost abolished the levels of phosphorylated and hyperpho-
sphorylated NfH in the ELISA (data not shown) and considerably
increased the levels of dephosphorylated NfH. For this reason further
analysis will only consider data from untreated samples for hyper-/
phosphorylated NfH and ALP treated samples for data on depho-
sphorylated NfH (see Table 2).
Topography of NfH phosphoforms in control tissue
NfH phosphoform distribution
In control tissue we observed a rostro-caudal gradient of
phosphorylated (Fig. 5 and Table 2A) and dephosphorylated NfH
(Table 2B) with increasing concentrations from brain gray matter, to
brain white matter, to spinal cord white matter. This trend was
signiﬁcant for phosphorylated NfH (M–H χ2=12.37, pb0.01, Table 2A)
and dephosphorylated NfH (MH χ2=7.4, pb0.01, Table 2B).
Overall, the rostro-caudal gradient was most marked for
phosphorylated NfH in control tissue (F2,16=5.53, pb0.01) and to a
lesser degree for dephosphorylated NfH (F2,16=4.17, pb0.05). The
phosphorylated NfH levels were about 3 to 15-fold higher in control
spinal white matter compared to control brain gray matter or control
brain white matter (pb0.05, pb0.01, respectively). Thus the percen-
tage of phosphorylated NfH to the total soluble protein corresponds
to 0.04% in the grey matter, 0.54% in the white matter and 1.71% in
the spinal cord.
The dephosphorylated NfH levels were about 5-fold higher in
control spinal cord white matter compared to brain gray matter
(pb0.05) or brain white matter (pb0.05, Table 2B).For hyperphosphorylated NfH the bulk of the protein was found in
the control brain white matter (F2,16=6.79, pb0.01) with levels being
about 17-fold above levels in control brain gray matter (pb0.01) and
about 10-fold higher than levels of spinal cord hyperphosphorylated
NfH (pb0.01, Table 2A).
Distribution of NfH phosphoforms in MS
Brain gray matter
There were no signiﬁcant differences between controls and MS
patients for any of the NfH phosphoforms (Table 2A and B).
Brain white matter
Signiﬁcant differences in tissue levels were found in NAWM, AL
and CL, for phosphorylated NfH (F3,20=3.34, pb0.05), hyperpho-
sphorylated NfH (F3,20=8.44, pb0.001) and dephosphorylated NfH
(F3,20=5.66, pb0.01). The highest levels of phosphorylated and
hyperphosphorylated NfH were found in AL (Table 2A). Signiﬁcances
were conﬁrmed on a categorical level by Fisher's exact test (Figs. 6A
and B). Dephosphorylated NfH was found to be highest in NAWM
(Table 2B, Fig. 7A).
Spinal cord white matter
Signiﬁcant differences in tissue levels were found for hyperphos-
phorylated NfH (F3,24=3.24, pb0.05) and dephosphorylated NfH
(F3,24=5.30, pb0.01). Levels of hyperphosphorylated NfH were signi-
ﬁcantly higher in AL compared to control tissue (Table 2A and Fig.
6D). Dephosphorylated NfH was lowest in CL (Table 2B and Fig. 7B).
Differences between MS brain and spinal cord
The concentration of phosphorylated NfH was 2 to 8-fold higher in
the spinal cord than in the brain for MS white matter (pb0.01) and CL
(pb0.01). In contrast, dephosphorylated NfHwas 7 to 13-fold higher in
the brain compared to the spinal cord white matter (pb0.05) and CL
Table 2
Brain gray matter, white matter and spinal cord white matter tissue homogenate levels of (A) phosphorylated/hyperphosphorylated NfH in tissue homogenate and (B) enzymatically
dephosphorylated NfH
NfH per μg/mg protein CTRL MS AL CL Signiﬁcance
(A)
Brain GM:
Phosphorylated (median) (IQR, n) 1.15 (0.14–1.90, 6) 2.07 (1.63–3.05, 6) – – NS
Hyperphosphorylated 0.41 (0.22–0.78, 6) 0.24 (0.17–0.58, 6) – – NS
Brain WM:
Phosphorylated 5.47 (2.05–6.87, 6) 5.15 (3.30–5.47, 6) 12.8 (9.68–16.78, 6) 5.52 (3.98–6.87, 6) pb0.05a
Hyperphosphorylated 6.82 (4.90–8.16, 6) 2.45 (0.76–6.73, 6) 28.7 (26.59–46.02, 6) 2.96 (0.67–5.26, 6) pb0.001b p=0.001c
Spinal WM:
Phosphorylated 17.17 (8.44–25.92, 7) 43.65 (17.69–72.57, 7) 19.69 (12.46–60.38, 7) 13.93 (13.94–33.38, 7) NS
Hyperphosphorylated 0.73 (0.40–0.86, 7) 2.21 (0.50–8.73, 7) 5.03 (3.62–86.27, 7) 5.21 (1.46–8.58, 7) pb0.01d
(B)
Brain GM:
Dephosphorylated 1.37 (0.62–2.64, 6) 1.34 (1.31–3.12, 5) – – NS
Brain WM:
Dephosphorylated 2.04 (0.31–3.05, 6) 15.29 (12.38–21.37, 6) 7.22 (2.45–10.12, 6) 3.73 (2.39–4.87, 6) pb0.01e pb0.05f
Spinal WM:
Dephosphorylated 10.46 (1.21–18.55, 7) 2.07 (1.42–5.40, 7) 9.12 (4.05–12.22, 7) 0.27 (0.15–1.08, 7) pb0.01g
The median value (IQR, n) are shown for normal control white matter (CTRL), normal-appearing white/gray matter (MS), acute lesions (AL) and chronic lesions (CL). The p-values are
given if the GLM allowed for post-hoc analysis, NS=not signiﬁcant.
a AL versus CTRL, AL versus MS (NAWM) and AL versus CL.
b AL versus CTRL.
c AL versus MS (NAWM) and AL versus CL.
d AL versus CTRL.
e MS (NAWM) versus CTRL and MS (NAWM) versus CL.
f MS(NAWM) versus CTRL.
g CL versus CTRL and AL versus CL.
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sphorylated NfH in the control tissue (see above and Table 2B).
Image analysis
The electron micrograph of the axonal ultrastructure is shown in
Fig. 8. The images demonstrate the more disorderly axonal cytoske-
leton in NAWM if compared to control white matter. Additionally, the
spacing between the intermediate ﬁlaments is larger, suggestive of
reduced compactness of Nfs in NAWM.
Samples from the periventricular control tissue and NAWM of the
frontal periventricular white matter were analysed. A median ofFig. 5. Rostro-caudal gradientof phosphorylatedNfH incontrol tissuehomogenate (mean±
SD). There was a signiﬁcant trend for increasing levels of phosphorylated NfH from brain
gray matter to brain white matter to spinal cord white matter (MH χ2=12.37, pb0.001).3016 (636–20849) pixels per axon were examined from slides
stained for SMI32 with and without ALP treatment. The median
axonal diameter was 5.8 (3.0–23.3) pixels. There was a Gaussian
distribution for small axons (≤10 pixels) and a bimodal distribution
for large axons (data not shown). The median axonal OD was 81.1
(4.9–283.4, arbitrary units). There was no signiﬁcant difference in
axonal size between control tissue and NAWM with a median dia-
meter of 15 pixels for large and 5.8 pixels for small axons for either
experiment.
Enzymatic dephosphorylation with ALP uniformly affected axonal
NfH compactness. There was a signiﬁcant difference in the OD bet-
ween groups (F3,156=87.15, pb0.0001). The post-hoc analysis showed
that the OD was higher in ALP-treated slides comparing large axons of
control tissue (OD=160.17) with large axons in NAWM (OD=118.74,
pb0.001). Also, the OD of small axons in control tissue (OD=92.74)
was higher than in NAWM (OD=63.65, pb0.01). The OD was consis-
tently higher in all ALP-treated axons than in untreated axons
(pb0.001 for each comparison). This explains the increase of axonal
compactness of NfH after treatment with ALP in control tissue and
NAWM (pb0.001, p=0.001, respectively).
Indeed, axonal compactness of NfH was signiﬁcantly different
between groups (F3,156=37.76, pb0.001). The post-hoc analysis show-
ed a higher degree of axonal compactness of NfH in ALP-treated
control tissue compared to NAWM axons (pb0.001, Fig. 9).
Discussion
NfH topography and compactness in control tissue
The signiﬁcant trend for increasing concentrations of phosphory-
lated NfH (SMI 35, see Fig. 1) from the brain gray matter to brainwhite
matter to spinal cord white matter suggests an increase in parenchy-
mal axonal density. These results are consistent with recently reported
ﬁndings in rodents (Shaw et al., 2005).
In view of the high levels of hyperphosphorylated NfH (SMI 34)
in brain white matter, the ﬁnding of a rostro-caudal gradient for
dephosphorylated NfH (SMI 32) needs to be interpreted on basis of
the original work on enzymatic dephosphorylation by ALP (refer to
Fig. 6. Tissue homogenate levels of (A) phosphorylated NfH and (B) hyperphosphorylated NfH in the brainwhite matter, (C) phosphorylated and (D) hyperphosphorylated NfH in the
spinal cord white matter. Levels are shown in μg/mg protein (mean±SD). Levels of signiﬁcance are indicated in the graph (Fisher's exact test) and the cut-off value is shown (dotted
line).
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epitopes by dephosphorylation, (Sternberger and Sternberger, 1983)
causes conformational changes, or releases NfH from protein/orga-
nelle binding (i.e. binding to microtubules). It was also suggested
that phosphorylation increases compactness and order in Nf struc-
ture (Sternberger and Sternberger, 1983). In contrast, the depho-
sphorylated forms of Nf are more easily transported along the
microtubule tracks, and the degree of phosphorylation correlated
inversely with the velocity of axonal transport (Watson et al., 1989).
The present ﬁndings suggest that the degree of NfH phosphory-
lation and compaction may increase from the brain gray matter to
white matter and further to the long tract axons of the spinal cord. We
believe this is of biological relevance as will be seen below.NfH levels are reduced in chronic lesions
Both for brain and spinal cord tissue the lowest levels of
dephosphorylated NfH were found in CL. This was consistent with
the immunocytochemical observation that staining for depho-
sphorylated NfH was reduced in CL and its border region. These
ﬁndings are in line with the observation of axonal loss in CL
(Ferguson et al., 1997; Trapp and Peterson, 1998; Lovas et al., 2000).
The more marked reduction of dephosphorylated NfH in CL of the
spinal cord compared to the brain, which in fact is the inverse
pattern to what we observed in control tissue, suggests some
heterogeneity of the pathological process affecting brain and spinal
cord axons.
Fig. 7. Tissue homogenate levels of dephosphorylated NfH in (A) the brainwhite matter and (B) the spinal cord white matter. Levels are shown in μg/mg protein (mean±SD). Levels of
signiﬁcance are indicated in the graph (Fisher's exact test) and the cutoff value is shown (dotted line).
333A. Petzold et al. / Experimental Neurology 213 (2008) 326–335Phosphorylated NfH appeared to “pile up” at the border of the CL
(Fig. 4A–D). This contamination with phosphorylated NfH from the
border region probably explains why, in contrast to dephosphorylated
NfH, no signiﬁcant difference was found compared to NAWM.Fig. 8. The ultrastructure of axons from the frontal periventricular white matter of (A)
controls and (B) NAWM fromMS patients is shown. The electron micrographs of several
myelinated and unmyelinated axons illustrate the more fragmented ultrastructure of
axons in NAWM. Additionally the density of the axonal cytoskeleton is less compact in
NAWM axons. This is best appreciated in the inlay which shows an enlarged copy of two
myelinated and approximately equally sized axons (indicated by a star and rotated by
90° for better visibility). Scale bars 2 µm.NfH phosphorylation is abnormal in NAWM
The ﬁnding of enzymatically dephosphorylated NfH levels being
approximately 7-fold higher in NAWM compared to control tissue, is
corroborated by our immunocytochemical results. This difference is
better appreciated from ELISA results, probably owing to a more
effective exposure of epitopes during protein extraction if compared to
antibody incubation of the intact tissue slide. This probably indicatesFig. 9. The compactness of axonal NfH is expressed as the ratio of OD to axonal diameter
(mean±SD) as explained in the methods. Compactness of NfH is signiﬁcantly higher in
ALP treated tissue homogenate from control compared to MS white matter. This effect
was not observed in untreated tissue. Levels of signiﬁcance are indicated (GLM, post-
hoc analysis, see text).
334 A. Petzold et al. / Experimental Neurology 213 (2008) 326–335an increase of aberrantly phosphorylated and/or aggregated NfH in
brainwhite matter axons of these patients with secondary progressive
MS. Not only is there an absolute increase of dephosphorylatedNfH but
the electron micrographs and image analysis also suggest that it is
more diffusely distributed within the NAWM axons. Compared to
control tissue axonal compactness of NfH was signiﬁcantly reduced in
NAWM. Importantly, this was independent of axonal diameter. This
ﬁnding extends previous observations, (Sternberger and Sternberger,
1983) and suggests post-translational alterations of the axoskeleton at
early stages of axonal pathology. We note that because all PM tissue
was from patients with secondary progressive MS it is not possible to
say from our data whether changes in NfH phosphorylation are a
feature at onset of the disease. In order to address this question future
studies may require biopsy material from patients with a clinical
isolated syndrome or early relapsing remmitting MS. Because the
increase of axonal compactness of NfH was only observed after
incubationwith ALP, we suggest that epitopes were hidden and/or the
protein was bound, i.e. to microtubules and that initially the epitopes
were not accessible to the SMI32 antibody.
NfH phosphorylation is increased in acute MS lesions
The highest levels of phosphorylated and hyperphosphorylated
NfHwere found in AL (Fig. 3). Immunocytochemistry results showed a
high amount of staining for SMI34 and SMI35 in axonal end-bulbs and
thick axons bordering the AL. This suggests a volume-effect of
accumulated phosphorylated and hyperphosphorylated NfH in this
region which is greater than the relative NfH scarcity in the centre of
the plaque, but the possibility of an additional extracellular compo-
nent also needs to be considered. The existence of extracellular,
mainly aggregated and phosphorylated NfH is known in the dementia
literature (reviewed in (Petzold, 2005). Extracellular NfH which is not
bound to tangles might be disregarded as non-speciﬁc background
and thus escape the immunocytochemical observation. Consistent
with one (Bitsch et al., 2000) but in contrast to other immunocyto-
chemical observations (Trapp and Peterson, 1998; Geurts et al., 2003;
Pitt et al., 2000; Gilgun-Sherki et al., 2003; Werner et al., 2001) we
were not able to demonstrate a quantitative difference for hypo-
phosphorylated NfH levels between AL, SAL and CL (data not shown).
Thismay in part be related to the susceptibility of non-phosphorylated
Nf to proteolysis (Sternberger and Sternberger, 1983; Goldstein et al.,
1987; Pant, 1988).
Is axonal transport in spinal cord axons impaired in MS?
The degree of NfH phosphorylation along the rostro-caudal
gradient was substantially increased in MS if compared to CTRL
tissue. Because NfH phosphorylation and axonal transport are in-
versely correlated (Watson et al., 1989; Ackerley and Grierson, 2000)
this suggests an impairment of the axonal transport machinery,
particularly in the long tract axons of the MS spinal cord. Impaired
axonal transport may be an important pathological feature to be
studies in demyelinating disease because of the intriguing relation-
ship with dying back neuropathy (Coleman and Perry, 2002). Dying
back neuropathy affects the proximal axon, but does not necessarily
require axonal transection and also occurs diffusely e.g. in the context
of chemotherapy, mitochondrial dysfunction or axonal Ca-overload. In
contrastWallerian degeneration affects axonal compartments distal to
the lesion (Vargas and Barres, 2007). In MS Wallerian degeneration it
thought to be the main mechanism by which axons degenerate,
(Ferguson et al., 1997; Trapp and Peterson, 1998; Bitsch et al., 2000) a
hypothesis supported by brain imaging techniques investigating
axonal tract integrity distal to the lesion site (Ciccarelli et al., 2003).
In the CNS axonal degeneration following injury may be substantially
slower than in the PNS and take up to several years (Vargas and Barres,
2007). This is thought to be related to slow clearance of myelin-associated inhibitors of axonal growth such as myelin-associated
glycoprotein (MAG), NogoA, oligodendrocyte-myelin glycoprotein
(OMgp), semaphorin 4D and ephrin B3 (Vargas and Barres, 2007).
Unfortunately, our study was designed to use de-lipidised samples
preventing us from further investigating this exciting hypothesis on
the present dataset, but future studies may be informative. Because
Wallerian degeneration is irreversible, but dying back neuropathy
may potentially be prevented it would be extremely important to try
separating these two processes in MS. If, as suggested by the present
data, dying back neuropathy should be a consistent feature in the MS
CNS tissue, then such knowledge could guide the development of
future neuroprotective treatment strategies.
A caveat of this study is that spinal cord tissue was taken only
from patients with SPMS and an EDSS of 9 to 10, likely to represent
the “burnt-out” phase of the disease. On basis of the MRI data, one
would have expected to ﬁnd severe atrophy in these spinal cords
(Losseff et al., 1996). The almost complete absence of dephospho-
rylated NfH in CL of the spinal cord also supports the idea that tissue
containing predominantly “burnt-out” axons has been sampled. In-
deed, in patients with primary and secondary progressive MS we
found an increase of phosphorylated and hyperphosphorylated NfH
in the cerebrospinal ﬂuid over a 3-year period (Petzold et al., 2005).
An interesting speculation is that spinal cord axons might differ from
brain tissue axons, thus contributing to the more insidious and
inexorable progress of disease once affected. One biological explana-
tion for this could be that for “topographical reasons of function” the
spinal cord has to be hostile to axonal sprouting by exploiting the
growth-inhibiting properties of proteins as mentioned above, the
inhibition of which may be a new neuroprotective strategy in EAE
(Karnezis et al., 2004). A 20 kDa soluble Nogo-A fragment (an axonal
growth inhibitor (Schwab, 2004) was recently found to be present in
96% of CSF samples fromMS patients, but none of the control patients
(Jurewicz et al., 2007).
Conclusion
In summary our data provides evidence that the proportion of
dephosphorylated NfH is increased in MS. Whilst NfH is transported
through the NAWM towards the MS plaque it may become aberrantly
phosphorylated and/or aggregate and probably slow axonal transport
itself. As NfH reaches the border of the acute plaque and in the spinal
cord it becomes hyperphosphorylated. Quantiﬁcation of NfH phos-
phoforms may provide a valuable tool to investigate the enzymatic
machinery involved in the dynamics of neuro-axonal degeneration.References
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